Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
Angiotensin-Converting Enzyme 2
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
COVID-19
/ prevention & control
COVID-19 Vaccines
/ immunology
Capsid
/ immunology
Female
Humans
Immunogenicity, Vaccine
Kinetics
Mice
Mice, Inbred BALB C
Protein Binding
/ genetics
Recombinant Proteins
/ genetics
SARS-CoV-2
/ immunology
Serologic Tests
Spike Glycoprotein, Coronavirus
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
17
07
2020
accepted:
23
11
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
20
1
2021
Statut:
epublish
Résumé
The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.
Identifiants
pubmed: 33436573
doi: 10.1038/s41467-020-20251-8
pii: 10.1038/s41467-020-20251-8
pmc: PMC7804149
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Recombinant Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
324Références
WHO/Europe | Coronavirus disease (COVID-19) outbreak - 2019-nCoV outbreak is an emergency of international concern. Available at: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/01/2019-ncov-outbreak-is-an-emergency-of-international-concern . (Accessed: 7th July 2020)
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
pubmed: 32007145
pmcid: 7159086
doi: 10.1016/S0140-6736(20)30251-8
Chen, J. et al. Receptor-binding domain of SARS-Cov spike protein: Soluble expression in E.coli, purification and functional characterization. World J. Gastroenterol. 11, 6159–6164 (2005).
pubmed: 16273643
pmcid: 4436633
doi: 10.3748/wjg.v11.i39.6159
Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
pubmed: 32132184
pmcid: 7164635
doi: 10.1126/science.abb2762
Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 17, 613–620 (2020).
pubmed: 32203189
doi: 10.1038/s41423-020-0400-4
pmcid: 7091888
Du, L. et al. The spike protein of SARS-CoV - A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009).
pubmed: 19198616
pmcid: 2750777
doi: 10.1038/nrmicro2090
Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182, 1–12 (2020).
doi: 10.1016/j.cell.2020.05.025
Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 1–8 (2020). https://doi.org/10.1038/s41586-020-2380-z
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 1–6 (2020). https://doi.org/10.1038/s41586-020-2349-y
Seydoux, E. et al. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. bioRxiv 2020.05.12.091298 (2020). https://doi.org/10.1101/2020.05.12.091298
Zost, S. J. et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. bioRxiv Prepr. Serv. Biol. 2020.05.22.111005 (2020). https://doi.org/10.1101/2020.05.22.111005
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 1–8 (2020). https://doi.org/10.1038/s41586-020-2180-5
Corbett, K. S. et al. SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. bioRxiv 2020.06.11.145920 (2020). https://doi.org/10.1101/2020.06.11.145920
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
pubmed: 32433465
pmcid: 7239918
doi: 10.1038/s41467-020-16505-0
Kim, E. et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine 55, 102743 (2020).
pubmed: 32249203
pmcid: 7128973
doi: 10.1016/j.ebiom.2020.102743
Doremalen, N. van et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv 2020.05.13.093195 (2020). https://doi.org/10.1101/2020.05.13.093195
Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (2020). https://doi.org/10.1016/S0140-6736(20)31208-3
Chen, W.-H. et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement. bioRxiv 2020.05.15.098079 (2020). https://doi.org/10.1101/2020.05.15.098079
Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science (80-.). eabc1932 (2020). https://doi.org/10.1126/science.abc1932
Thanh Le, T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305–306 (2020).
pubmed: 32273591
doi: 10.1038/d41573-020-00073-5
Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: status report. Immunity 52, 583–589 (2020).
pubmed: 32259480
pmcid: 7136867
doi: 10.1016/j.immuni.2020.03.007
Draft landscape of COVID-19 candidate vaccines. Available at: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines . (Accessed: 7th July 2020)
Thrane, S. et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J. Nanobiotechnology 14, 30 (2016).
pubmed: 27117585
pmcid: 4847360
doi: 10.1186/s12951-016-0181-1
Brune, K. D. et al. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci. Rep. 6, 1–13 (2016).
doi: 10.1038/srep19234
Tan, L. L., Hoon, S. S. & Wong, F. T. Kinetic controlled tag-catcher interactions for directed covalent protein assembly. PLoS ONE 11, 1–15 (2016).
doi: 10.1371/journal.pone.0165074
Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. PNAS 109, E690–E607 (2012).
pubmed: 22366317
doi: 10.1073/pnas.1115485109
pmcid: 3311370
Prö Schel, M. et al. Probing the potential of CnaB-type domains for the design of tag/catcher systems. https://doi.org/10.1371/journal.pone.0179740
Pumpens, P. et al. The true story and advantages of RNA phage capsids as nanotools. Intervirology 59, 74–110 (2016).
pubmed: 27829245
doi: 10.1159/000449503
Mohsen, M., Gomes, A., Vogel, M. & Bachmann, M. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. Vaccines 6, 1–12 (2018).
doi: 10.3390/vaccines6030037
Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451 (1993).
pubmed: 8248784
doi: 10.1126/science.8248784
Bachmann, M. F. & Zinkernagel, R. M. The influence of virus structure on antibody responses and virus serotype formation. Immunol. Today 17, 553–558 (1996).
pubmed: 8991286
doi: 10.1016/S0167-5699(96)10066-9
Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404–1413 (2008).
pubmed: 18389478
doi: 10.1002/eji.200737984
Alexander Titz, B. et al. Innate immunity mediates follicular innate immunity mediates follicular transport of particulate but not soluble protein antigen. J. Immunol. 188, 3724–3733 (2012).
pubmed: 22427639
doi: 10.4049/jimmunol.1103312
Jegerlehner, A. et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 32, 3305–3314 (2002).
pubmed: 12555676
doi: 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J
Leneghan, D. B. et al. Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Nat. Sci. Rep. 7, 1–14 (2017).
Bachmann, M. F. & Jennings, G. T. Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos. Trans. R. Soc. B Biol. Sci. 366, 2815–2822 (2011).
doi: 10.1098/rstb.2011.0103
Mohsen, M. O., Zha, L., Cabral-Miranda, G. & Bachmann, M. F. Major findings and recent advances in virus–like particle (VLP)-based vaccines. Semin. Immunol. 34, 123–132 (2017).
pubmed: 28887001
doi: 10.1016/j.smim.2017.08.014
Schiller, J. & Lowy, D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 36, 4768–4773 (2018).
pubmed: 29325819
pmcid: 6035892
doi: 10.1016/j.vaccine.2017.12.079
Schiller, J. T., Castellsagué, X. & Garland, S. M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30, F123–F138 (2012).
pubmed: 23199956
pmcid: 4636904
doi: 10.1016/j.vaccine.2012.04.108
De Vincenzo, R., Conte, C., Ricci, C., Scambia, G. & Capelli, G. Long-term efficacy and safety of human papillomavirus vaccination. Int. J. Women’s. Health 6, 999–1010 (2014).
doi: 10.2147/IJWH.S50365
Shishovs, M. et al. Structure of AP205 coat protein reveals circular permutation in ssRNA bacteriophages. J. Mol. Biol. 428, 4267–4279 (2016).
pubmed: 27591890
doi: 10.1016/j.jmb.2016.08.025
Li, L., Fierer, J. O., Rapoport, T. A. & Howarth, M. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide tag. J. Mol. Biol. 426, 309–317 (2014).
pubmed: 24161952
doi: 10.1016/j.jmb.2013.10.021
Fierer, J. O., Veggiani, G. & Howarth, M. SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture. Proc. Natl Acad. Sci. USA 111, E1176–E1181 (2014).
pubmed: 24639550
doi: 10.1073/pnas.1315776111
pmcid: 3977242
Hatlem, D., Trunk, T., Linke, D. & Leo, J. C. Catching a SPY: Using the SpyCatcher-SpyTag and related systems for labeling and localizing bacterial proteins. Int. J. Mol. Sci. 20, 1–19 (2019).
doi: 10.3390/ijms20092129
Buldun, C. M., Jean, J. X., Bedford, M. R. & Howarth, M. SnoopLigase catalyzes peptide-peptide locking and enables solid-phase conjugate isolation. J. Am. Chem. Soc. 140, 3008–3018 (2018).
pubmed: 29402082
doi: 10.1021/jacs.7b13237
Pröschel, M. et al. Probing the potential of CnaB-type domains for the design of tag/catcher systems. PLoS ONE 12, 1–26 (2017).
doi: 10.1371/journal.pone.0179740
Keeble, A. H. et al. Approaching infinite affinity through engineering of peptide–protein interaction. PNAS 1–11 (2019). https://doi.org/10.1073/pnas.1909653116
Coronavirus Update (Live): 11,756,506 Cases and 541,086 Deaths from COVID-19 Virus Pandemic - Worldometer. Available at: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1? (Accessed: 7th July 2020)
Moore, J. P. & Klasse, P. J. SARS-CoV-2 vaccines: ‘Warp Speed’ needs mind melds not warped minds. J. Virol. (2020). https://doi.org/10.1128/JVI.01083-20
Wang, L. et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J. Infect. 80, 639–645 (2020).
pubmed: 32240670
pmcid: 7118526
doi: 10.1016/j.jinf.2020.03.019
Antia, A. et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLOS Biol. 1–15 (2018). https://doi.org/10.1371/journal.pbio.2006601
Amanna, I. J. Balancing the efficacy and safety of vaccines in the elderly. Open Longev. Sci. 6, 64–72 (2012).
pubmed: 23565132
pmcid: 3616444
doi: 10.2174/1876326X01206010064
Lambert, P. H. et al. Consensus summary report for CEPI/BC March 12–13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine 38, 1–8 (2020).
doi: 10.1016/j.vaccine.2020.05.064
Kellam, P. & Barclay, W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J. Gen. Virol. jgv001439 (2020). https://doi.org/10.1099/jgv.0.001439
Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162–1163 (2007).
doi: 10.1056/NEJMc070348
pubmed: 17855683
Vabret, N. et al. Immunology of COVID-19: current state of the science. Cell Press Immun. 52, 910–941 (2020).
Simon, H.-U., Karaulov, A. V. & Bachmann, M. F. Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection. Int. Arch. Allergy Immunol. 1–5 (2020). https://doi.org/10.1159/000509368
Rogers, T. F. et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv 2020.05.11.088674 (2020). https://doi.org/10.1101/2020.05.11.088674
Escolano, A. et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature 570, 468–473 (2019).
pubmed: 31142836
pmcid: 6657810
doi: 10.1038/s41586-019-1250-z
Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615–632 (2020).
pubmed: 32887954
doi: 10.1038/s41577-020-00434-6
pmcid: 7472682
Podda, A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19, 2673–2680 (2001).
pubmed: 11257408
doi: 10.1016/S0264-410X(00)00499-0
Grunwald, T. & Ulbert, S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin. Exp. Vaccin. Res. 4, 1 (2015).
doi: 10.7774/cevr.2015.4.1.1
Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time? https://doi.org/10.1038/nrg2432
Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20 (2020).
pubmed: 32244193
doi: 10.1016/j.coi.2020.01.008
Jegerlehner, A. et al. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 28, 5503–5512 (2010).
pubmed: 20307591
doi: 10.1016/j.vaccine.2010.02.103
McCluskie, M. J. et al. The effect of preexisting anti-carrier immunity on subsequent responses to CRM 197 or Qb-VLP conjugate vaccines. Immunopharmacol. Immunotoxicol. 38, 184–196 (2016).
pubmed: 27121368
doi: 10.3109/08923973.2016.1165246
Janitzek, C. M. et al. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malar. J. 15, 1–9 (2016).
doi: 10.1186/s12936-016-1574-1
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hugiene 27, 493–497 (1938).
Hierholzer, J. C.; R. A. K. Virology Method Manual. in Virology Method Manual 374 (1996).